Page 9 - Column Group News Today

Tech industry defenders blame the media for hyping up Theranos founder Elizabeth Holmes as the next Steve Jobs while critics see Holmes as an example of tech hubris run amok. Either way, Silicon Valley has been scarred.

Tech industry defenders blame the media for hyping up Theranos founder Elizabeth Holmes as the next Steve Jobs while critics see Holmes as an example of tech hubris run amok. Either way, Silicon Valley has been scarred.

Tech industry defenders blame the media for hyping up Theranos founder Elizabeth Holmes as the next Steve Jobs while critics see Holmes as an example of tech hubris run amok. Either way, Silicon Valley has been scarred.

Adam Goulburn, a partner at Lux Capital, was first struck by Eikon Therapeutics’ pitch to use super microscopes to develop drugs when founder Eric Betzig posed a simple question: How can you understand life if you don’t look at it live?  “It was such a simple statement, but it was kind of eye opening to […]

- Alain Baron, M.D., Escient Co-founder and CEO Retires -SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, a clinical-stage company focused on discovering and developing novel, first-in-class therapies to address serious, unserved medical needs, today announced the appointment of Joshua Grass, MBA as Chief Execut...

Boylston Properties announces 100 Forge in Watertown is now fully leased to five life science companies.

Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors - read this article along with other careers information, tips and advice on BioSpace

/PRNewswire/ -- A2 Biotherapeutics, Inc., "A2 Bio", is a biotechnology company focused on the development of first-in-class T cell therapies to treat solid...

/PRNewswire/ -- The "Antibody Drug Conjugates Market by Indication, Linker, Payload, Target Antigens and Geography: Industry Trends and Global Forecasts,...

Atavistik Bio is one of several companies discovering and developing drugs that work by allostery, binding to less obvious sites of a target protein. Acting CEO John Josey said the startup aims to stand apart with its focus on understanding metabolic interactions, a path less trodden by others in allosteric drug discovery.